Abstract: A thiolation method for modifying nanodiamonds includes steps as follows. A carboxylation step is provided, wherein the nanodiamonds are reacted with an oxidant for generating carboxyl groups on surfaces of the nanodiamonds so as to form carboxylated nanodiamonds. A hydroxylation step is provided, wherein the carboxyl groups of the carboxylated nanodiamonds are transformed into hydroxyl groups so as to transform the carboxylated nanodiamonds into hydroxylated nanodiamonds. A thiolation step is provided. In the thiolation step, the hydroxylated nanodiamonds, a sulfur source and a first acidic substance are mixed and then stirred so as to form a first mixture, the first mixture is added portion-wisely into an alkaline solution so as to form a second mixture, and the second mixture is acidified so as to form an acidified solution having a pH value ranging from 2 to 3, thus the hydroxylated nanodiamonds are transformed into thiolated nanodiamonds.

Abstract: A thiolation method for modifying carbon nanotubes includes steps as follows. A carboxylation step is provided, wherein the carbon nanotubes are reacted with an oxidant for generating carboxyl groups on surfaces of the carbon nanotubes so as to form carboxylated carbon nanotubes. A hydroxylation step is provided, wherein the carboxyl groups are transformed into hydroxyl groups so as to transform the carboxylated carbon nanotubes into hydroxylated carbon nanotubes. A thiolation step is provided, wherein the hydroxylated carbon nanotubes, a sulfur source and a first acidic substance are mixed and then stirred so as to form a first mixture, the first mixture is added portion-wisely into an alkaline solution so as to form a second mixture, and the second mixture is acidified so as to form an acidified solution having a pH value ranging from 2 to 3, thus the hydroxylated carbon nanotubes are transformed into thiolated carbon nanotubes.

Abstract: A thiolation method for modifying carbon nanotubes includes steps as follows. A carboxylation step is provided, wherein the carbon nanotubes are reacted with an oxidant for generating carboxyl groups on surfaces of the carbon nanotubes so as to form carboxylated carbon nanotubes. A hydroxylation step is provided, wherein the carboxyl groups are transformed into hydroxyl groups so as to transform the carboxylated carbon nanotubes into hydroxylated carbon nanotubes. A thiolation step is provided, wherein the hydroxylated carbon nanotubes, a sulfur source and a first acidic substance are mixed and then stirred so as to form a first mixture, the first mixture is added portion-wisely into an alkaline solution so as to form a second mixture, and the second mixture is acidified so as to form an acidified solution having a pH value ranging from 2 to 3, thus the hydroxylated carbon nanotubes are transformed into thiolated carbon nanotubes.

Abstract: A thiolation method for modifying nanodiamonds includes steps as follows. A carboxylation step is provided, wherein the nanodiamonds are reacted with an oxidant for generating carboxyl groups on surfaces of the nanodiamonds so as to form carboxylated nanodiamonds. A hydroxylation step is provided, wherein the carboxyl groups of the carboxylated nanodiamonds are transformed into hydroxyl groups so as to transform the carboxylated nanodiamonds into hydroxylated nanodiamonds. A thiolation step is provided. In the thiolation step, the hydroxylated nanodiamonds, a sulfur source and a first acidic substance are mixed and then stirred so as to form a first mixture, the first mixture is added portion-wisely into an alkaline solution so as to form a second mixture, and the second mixture is acidified so as to form an acidified solution having a pH value ranging from 2 to 3, thus the hydroxylated nanodiamonds are transformed into thiolated nanodiamonds.

Abstract: The present invention relates to methods of inhibiting shikimate pathway, comprising administering to a subject a pharmaceutically acceptable composition comprising a compound having a formula: or pharmaceutically acceptable salts thereof.

Abstract: Novel compounds which are derivatives of tetra-O-methyl nordihydroguaiaretic acid (NDGA), as well as pharmaceutically acceptable salts, solvates, and stereoisomers thereof are provided. These NDGA derivatives have a nitroimidazole moiety and these derivatives show preferential toxicity to hypoxic cells as hypoxic cytotoxins. Their cytotoxicity toward hypoxic cells is a result of abstraction of hydrogen from target molecules by free radicals formed in the reduction of the nitro group. This makes the disclosed compounds an effective anti cancer drug because hypoxic cells are generally considered to be more resistant to anti cancer drugs than normal cells. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment for cancers, including hepatocellular carcinoma, breast cancer and prostate cancer, are also provided.

Abstract: The present invention relates to methods of inhibiting shikimate pathway, comprising administering to a subject a pharmaceutically acceptable composition comprising a compound having a formula: or pharmaceutically acceptable salts thereof.

Abstract: Novel compounds which are derivatives of tetra-O-methyl nordihydroguaiaretic acid (NDGA), as well as pharmaceutically acceptable salts, solvates, and stereoisomers thereof are provided. These NDGA derivatives have a nitroimidazole moiety and these derivatives show preferential toxicity to hypoxic cells as hypoxic cytotoxins. Their cytotoxicity toward hypoxic cells is a result of abstraction of hydrogen from target molecules by free radicals formed in the reduction of the nitro group. This makes the disclosed compounds an effective anti cancer drug because hypoxic cells are generally considered to be more resistant to anti cancer drugs than normal cells. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment for cancers, including hepatocellular carcinoma, breast cancer and prostate cancer, are also provided.

Abstract: Reaction of nordihydroguaiaretic acid with various alkyl chlorides, 1-piperidinecarbonyl chloride, methyl chloroformate, or 1,1?-carbonyldiimidazole under alkaline conditions produced the corresponding phenol ethers, carbamates and carbonates, respectively, in 67-83% yields (Scheme 1 and Scheme 2). Among these derivatives, the nitrogen-containing compounds were converted to the corresponding hydrochloride salts. Having good solubility, these NDGA derivatives were found to be stable in aqueous solution. These new compounds exerted potent activities against HIV Tat-regulated transactivation in cos-7 cells. The most active transcription inhibitor compound of this series 5b (P4N, Tetrapiperidino NDGA, meso-2,3-dimethyl-1,4-bis(3,4-[2-(piperidino)ethoxypehnyl])butane tetrakishydrochloride salt) has an IC50 of 0.88 ?M.

Abstract: Reaction of nordihydroguaiaretic acid with various alkyl chlorides, 1-piperidinecarbonyl chloride, methyl chloroformate, or 1,1?-carbonyldiimidazole under alkaline conditions produced the corresponding phenol ethers, carbamates and carbonates, respectively, in 67-83% yields (Scheme 1 and Scheme 2). Among these derivatives, the nitrogen-containing compounds were converted to the corresponding hydrochloride salts. Having good solubility, these NDGA derivatives were found to be stable in aqueous solution. These new compounds exerted potent activities against HIV Tat-regulated transactivation in cos-7 cells. The most active transcription inhibitor compound of this series 5b (P4N, Tetrapiperidino NDGA, meso-2,3-dimethyl-1,4-bis(3,4-[2-(piperidino)ethoxyphenyl])butane tetrakishydrochloride salt) has an IC50 of 0.88 ?M.

Abstract: Compositions and methods for using nordihydroguaiaretic acid (NDGA) derivatives for preventing the expression of MDR-1 gene and the synthesis of PgP protein or reversing multiple drug resistance in cells, and for using NDGA derivatives in combination with additional chemotherapeutic agents to treat drug resistant cancer and infections.